Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mineralys Therapeutics, Inc. - Common Stock (NQ:MLYS)

28.31 +0.08 (+0.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mineralys Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock? ↗
This clinical-stage biotech focused on hypertension therapies reported a notable insider sale, according to new SEC filings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗
This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗
This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications. 
Via The Motley Fool
Topics Regulatory Compliance
Mineralys Therapeutics Inc (NASDAQ:MLYS) Reports Q4 2025 EPS Beat and Key FDA NDA Acceptance for Lorundrostat ↗
Via Chartmill
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Earnings Preview For Mineralys Therapeutics ↗
 
Via Benzinga
News headline image
Mineralys (MLYS) Q4 2025 Earnings Call Transcript ↗
Mineralys (MLYS) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears ↗
When a clinical-stage biotech is sitting on nearly $600 million in cash and lining up an FDA filing, sharp investors stop arguing about the past rally and start debating what comes next. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys ↗
One small fund’s high-conviction move offers a window into how specialists are navigating 2025’s biotech rally. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
MINERALYS THERAPEUTICS INC (NASDAQ:MLYS) Beats Q3 2025 EPS Estimates and Advances Key Drug Candidate ↗
Mineralys Therapeutics beat Q3 2025 EPS estimates. The biotech firm is advancing its lead drug, lorundrostat, toward a planned FDA submission. 
Via Chartmill
News headline image
Uncovering Potential: Mineralys Therapeutics's Earnings Preview ↗
 
Via Benzinga
News headline image
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? ↗
Here's what needs to happen for these high flyers to continue soaring. 
Via The Motley Fool
News headline image
It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps ↗
A new market leader has snuck into town over the past month as Small Caps have pushed to the top of the leader board. Whether the trend lasts, or not, will depend a lot on what the Fed does, but one... 
Via The Motley Fool
Topics Economy Stocks
News headline image
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts ↗
Experts who follow these stocks think they can fly higher despite already gaining over 100% since the end of July. 
Via The Motley Fool
News headline image
Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Here are the top movers in Tuesday's session. ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session. ↗
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Nasdaq Down 1%; Signet Jewelers Earnings Top Views ↗
 
Via Benzinga
News headline image
Tuesday's pre-market session: top gainers and losers ↗
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results ↗
AstraZeneca, on Saturday, unveiled promising results for a new hypertension treatment that aims to help the roughly 650,000 people. 
Via Investor's Business Daily
News headline image
Nasdaq 100, S&P 500 Hit New All-Time Highs, Airlines Jump: What's Moving Markets Tuesday? ↗
Wall Street is in full rally mode after July’s inflation data eased fears that tariff-related cost pressures were widespread. The headline Consumer Price Index (CPI) came in below expectations, holding... 
Via Benzinga
Topics Economy Stocks
News headline image
Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps ↗
Mineralys reports Phase 2 trial success for lorundrostat, showing BP and kidney improvements in CKD patients with favorable safety results. 
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.